A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Exclusion Criteria

• •Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra 223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the CRPC setting for the treatment of prostate cancer or participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless treatment was placebo);
• •Treatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy) within 4 weeks before enrollment;
• •Initiation of new treatment with denosumab, bisphosphonates, or systemic corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;
• •Use of an investigational agent within 4 weeks before the screening visit;
• •Radiation therapy to bone within 4 weeks before enrollment;
• •Use of opiate analgesics for prostate cancer pain within 4 weeks before enrollment;
• •Screening 99mTc-MDP bone scintigraphy showing a superscan;
• •Visceral (eg, lung, liver) metastatic disease. Adenopathy is allowed;
• •Current or previously treated brain metastasis or active leptomeningeal disease;
• •History of seizure any time in the past for any reason or any condition that may predispose to seizures.